Press Releases
June 20, 2022
Surface Oncology Announces Publication of New Study Demonstrating the Role of the IL-27 Pathway in Hepatocellular Carcinoma
June 3, 2022
Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 1, 2022
Surface Oncology to Participate in Upcoming Investor Conferences
May 26, 2022
Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
May 17, 2022
Surface Oncology to Participate in Upcoming Investor Conferences
May 9, 2022
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2022
May 6, 2022
Surface Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 27, 2022
Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting
April 21, 2022
Surface Oncology Named one of the 2022 Best Places to Work by Boston Business Journal
April 14, 2022
Surface Oncology Announces Initiation of Phase 2 Studies Evaluating SRF388 in Patients with Hepatocellular Carcinoma and Non-Small-Cell Lung Cancer
Displaying 1 - 10 of 17